Pulmonx publishes investor presentation on Zephyr endobronchial valves for severe emphysema treatment
PUBT · 1d ago
Share
Listen to the news
- Pulmonx highlighted a USD 12 billion market opportunity for Zephyr endobronchial valves in severe emphysema.
- Reported 2Q26 revenue of USD 22.8 million, including USD 14.2 million in the US, with gross margin of 78%.
- Cash, cash equivalents, and marketable securities totaled USD 55.8 million as of 6/30/2026.
- Noted more than 50,000 patients treated globally, supported by four randomized trials and more than 100 scientific publications.
- Outlined AeriSeal as an investigational program aimed at converting some ineligible patients, with potential to expand addressable market by at least 20%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved